Ouagazzal A M, Creese I
Preclinical Research, Pharmaceuticals Division, F. Hoffmann-La Roche, PRPN, CH-4070, Basel, Switzerland.
Pharmacol Biochem Behav. 2000 Nov;67(3):637-45. doi: 10.1016/s0091-3057(00)00406-8.
The present study investigated whether PD 128907 and 7-OH-DPAT, described as preferential dopamine (DA) D(3) receptor agonists, produce hypolocomotion by acting at postsynaptic dopaminergic receptors within the nucleus accumbens. Bilateral infusion of PD 128907 (1.5 and 3 microg/0.5 microl) induced a dose-dependent hypolocomotion, whereas its enantiomer, PD 128908, was inactive. Local infusion of 7-OH-DPAT and the preferential DA autoreceptor agonist, B-HT 920, at the same dose range also decreased spontaneous locomotion. In addition, both drugs induced yawning with B-HT 920 producing the greatest effect. In the second experiment, the ability of these agonists to reduce the locomotor activity induced by intra-accumbens injection of DA (10 microg/0.5 microl) was studied. Pretreatment with either PD 128907 or 7-OH-DPAT (3 microg) reduced DA-induced hyperactivity. Local infusion of B-HT 920 (3 microg) failed to antagonise the locomotor effects of DA. Altogether these findings suggest that PD 128907 and 7-OH-DPAT induce hypolocomotion by acting in part at postsynaptic DA receptors. The possible role of D(2) and/or D(3) receptors in the mediation of these effects is discussed.
本研究调查了被描述为选择性多巴胺(DA)D(3)受体激动剂的PD 128907和7-羟基-DPAT是否通过作用于伏隔核内的突触后多巴胺能受体而产生运动减少。双侧注射PD 128907(1.5和3微克/0.5微升)可诱导剂量依赖性的运动减少,而其对映体PD 128908则无活性。在相同剂量范围内局部注射7-羟基-DPAT和选择性DA自身受体激动剂B-HT 920也可降低自发运动。此外,两种药物均可诱导打哈欠,其中B-HT 920的作用最为明显。在第二个实验中,研究了这些激动剂降低伏隔核内注射DA(10微克/0.5微升)所诱导的运动活性的能力。用PD 128907或7-羟基-DPAT(3微克)预处理可降低DA诱导的多动。局部注射B-HT 920(3微克)未能拮抗DA的运动效应。总之,这些发现表明PD 128907和7-羟基-DPAT部分通过作用于突触后DA受体而诱导运动减少。文中还讨论了D(2)和/或D(3)受体在介导这些效应中的可能作用。